We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cencora Inc | NYSE:COR | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.09 | -0.04% | 221.76 | 223.05 | 221.029 | 222.74 | 188,864 | 16:27:54 |
Revenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year
First Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28
Adjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024
Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 first quarter ended December 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased 21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter.
Cencora is updating its outlook for fiscal year 2024. The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2024 Expectations. Adjusted diluted EPS guidance has been raised from the previous range of $12.70 to $13.00 to a range of $13.25 to $13.50.
“Cencora had an exceptional start to our fiscal 2024 year, delivering strong results as we capitalize on the strength of the trends in our business, continue to prioritize customer centricity and enhance the services we provide, further differentiating the value we bring to our customers and stakeholders,” said Steven H. Collis, Chairman, President, and Chief Executive Officer at Cencora.
“As we look ahead to the rest of our fiscal year, we are focused on executing on our pharmaceutical-centric strategy and capturing opportunities through the robust capabilities our business offers within the ever-changing healthcare landscape,” continued Mr. Collis. “I remain inspired by our team members’ drive to deliver on our purpose by demonstrating passion and adaptability as we work through a complex, global healthcare system to improve lives every day.”
First Quarter Fiscal Year 2024 Summary Results
GAAP
Adjusted (Non-GAAP)
Revenue
$72.3B
$72.3B
Gross Profit
$2.5B
$2.4B
Operating Expenses
$1.6B
$1.5B
Operating Income
$823M
$886M
Interest Expense, Net
$41M
$41M
Effective Tax Rate
23.0%
21.0%
Net Income Attributable to Cencora, Inc.
$602M
$661M
Diluted Earnings Per Share
$2.98
$3.28
Diluted Shares Outstanding
201.8M
201.8M
Below, Cencora presents descriptive summaries of the Company’s GAAP and adjusted (non-GAAP) quarterly results. In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. For more information related to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the “Supplemental Information Regarding Non-GAAP Financial Measures” following the tables.
First Quarter GAAP Results
First Quarter Adjusted (non-GAAP) Results
Segment Discussion
The Company is organized geographically based upon the products and services it provides to its customers under two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions.
U.S. Healthcare Solutions
U.S. Healthcare Solutions revenue was $65.2 billion in the first quarter of fiscal 2024, an increase of 15.9 percent compared to the same quarter in the previous fiscal year due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class, increased sales of specialty products to physician practices and health systems, and increased sales of COVID-19 vaccines. Segment operating income of $698.1 million in the first quarter of fiscal 2024 was up 22.0 percent compared to the same period in the previous fiscal year reflecting an increase in gross profit, partially offset by an increase in operating expenses.
International Healthcare Solutions
Revenue in International Healthcare Solutions was $7.1 billion in the first quarter of fiscal 2024, an increase of 6.9 percent from the previous fiscal year’s first quarter primarily due to increased sales in our European distribution business and increased sales in our Canadian business. Segment operating income in the first quarter of fiscal 2024 was $187.6 million, an increase of 16.3 percent, primarily due to higher operating income at our global specialty logistics business, the January 2023 acquisition of PharmaLex, and growth at our Canadian business, partially offset by foreign currency pressure and higher information technology expenses in our European distribution business, and the September 2023 divestiture of the Company’s less-than-wholly-owned subsidiary in Egypt, which was profitable in the prior year quarter. On a constant currency basis, International Healthcare Solutions revenue and operating income increased by 8.7 percent and 20.2 percent, respectively.
Recent Company Highlights & Milestones
Fiscal Year 2024 Expectations
The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available or cannot be reasonably estimated. Please refer to the Supplemental Information Regarding Non-GAAP Financial Measures following the tables for additional information.
Fiscal Year 2024 Expectations on an Adjusted (non-GAAP) Basis
Cencora is updating its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year, including the incremental contributions from commercial COVID-19 vaccine distribution in the first quarter. The Company’s previously communicated expectations for exclusive COVID-19 treatment contributions remain unchanged. The Company now expects:
Additional expectations now include:
Dividend Declaration
The Company’s Board of Directors declared a quarterly cash dividend of $0.51 per common share, payable February 26, 2024, to stockholders of record at the close of business on February 9, 2024.
Conference Call & Slide Presentation
The Company will host a conference call to discuss the results at 8:30 a.m. ET on January 31, 2024. A slide presentation for investors has also been posted on the Company’s website at investor.cencora.com. Participating in the conference call will be:
The dial-in number for the live call will be (833) 470-1428. From outside the United States and Canada, dial +1 (404) 975-4839. The access code for the call will be 457478. The live call will also be webcast via the Company’s website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.
Replays of the call will be made available via telephone and webcast. A replay of the webcast will be posted on investor.cencora.com approximately one hour after the completion of the call and will remain available for one year. The telephone replay will also be available approximately one hour after the completion of the call and will remain available for seven days. To access the telephone replay from within the U.S. and Canada, dial (866) 813-9403. From outside the United States, dial +1 (929) 458-6194. The access code for the replay is 308642.
Upcoming Investor Event
Cencora management will be attending the following investor event in the coming months:
Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.
About Cencora
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $250 billion in annual revenue. Learn more at investor.cencora.com
Cencora’s Cautionary Note Regarding Forward-Looking Statements
Certain of the statements contained in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act”). Words such as “aim,” “anticipate,” “believe,” “can,” “continue,” “could,”, “estimate,” "expect," “intend,” “may,” “might,” “on track,” “opportunity,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “sustain,” “synergy,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially from those indicated is included in the “Risk Factors” and “Management’s Discussion and Analysis” sections in the Company’s Annual Report on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.
CENCORA, INC.
FINANCIAL SUMMARY
(in thousands, except per share data)
(unaudited)
Three Months Ended December 31, 2023
% of
Revenue
Three Months Ended December 31, 2022
% of
Revenue
%
Change
Revenue
$
72,252,833
$
62,846,832
15.0
%
Cost of goods sold
69,784,021
60,700,879
15.0
%
Gross profit 1
2,468,812
3.42
%
2,145,953
3.41
%
15.0
%
Operating expenses:
Distribution, selling, and administrative
1,398,747
1.94
%
1,290,928
2.05
%
8.4
%
Depreciation and amortization
270,603
0.37
%
171,940
0.27
%
57.4
%
Litigation and opioid-related (credit) expenses 2
(78,917
)
12,706
Acquisition-related deal and integration expenses
21,063
20,996
Restructuring and other expenses
34,441
16,240
Total operating expenses
1,645,937
2.28
%
1,512,810
2.41
%
8.8
%
Operating income
822,875
1.14
%
633,143
1.01
%
30.0
%
Other income, net
(1,087
)
(6,328
)
Interest expense, net
40,564
46,016
(11.8
)%
Income before income taxes
783,398
1.08
%
593,455
0.94
%
32.0
%
Income tax expense
180,390
117,285
Net income
603,008
0.83
%
476,170
0.76
%
26.6
%
Net (income) loss attributable to noncontrolling interests
(1,508
)
3,575
Net income attributable to Cencora, Inc.
$
601,500
0.83
%
$
479,745
0.76
%
25.4
%
Earnings per share:
Basic
$
3.01
$
2.35
28.1
%
Diluted
$
2.98
$
2.33
27.9
%
Weighted average common shares outstanding:
Basic
200,081
204,032
(1.9
)%
Diluted
201,837
206,327
(2.2
)%
________________________________________1
Includes a $48.2 million gain from antitrust litigation settlements, a $48.4 million LIFO credit, and Turkey foreign currency remeasurement expense of $17.2 million in the three months ended December 31, 2023. Includes a $49.9 million gain from antitrust litigation settlements, a $25.1 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6 million in the three months ended December 31, 2022.
2
The three months ended December 31, 2023 includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company’s commitment, which it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid settlement agreements.
CENCORA, INC.
GAAP TO NON-GAAP RECONCILIATIONS
(in thousands, except per share data)
(unaudited)
Three Months Ended December 31, 2023
Gross Profit
Operating Expenses
Operating Income
Income Before Income Taxes
Income Tax
Expense
Net Income Attributable to Noncontrolling Interests
Net Income Attributable to Cencora
Diluted Earnings Per Share
GAAP
$
2,468,812
$
1,645,937
$
822,875
$
783,398
$
180,390
$
(1,508
)
$
601,500
$
2.98
Gains from antitrust litigation settlements
(48,248
)
—
(48,248
)
(48,248
)
(10,456
)
—
(37,792
)
(0.19
)
LIFO credit
(48,445
)
—
(48,445
)
(48,445
)
(10,498
)
—
(37,947
)
(0.19
)
Turkey highly inflationary impact
17,226
—
17,226
16,919
—
—
16,919
0.08
Acquisition-related intangibles amortization
—
(165,724
)
165,724
165,724
35,913
(435
)
129,376
0.64
Litigation and opioid-related credit, net 1
—
78,917
(78,917
)
(78,917
)
(12,028
)
—
(66,889
)
(0.33
)
Acquisition-related deal and integration expenses
—
(21,063
)
21,063
21,063
4,564
—
16,499
0.08
Restructuring and other expenses
—
(34,441
)
34,441
34,441
7,463
—
26,978
0.13
Loss on remeasurement of equity investment
—
—
—
10,201
—
—
10,201
0.05
Other, net
—
—
—
222
(109
)
—
331
—
Tax reform 2
—
—
—
(16,685
)
(18,916
)
—
2,231
0.01
Adjusted Non-GAAP
$
2,389,345
$
1,503,626
$
885,719
$
839,673
$
176,323
$
(1,943
)
$
661,407
$
3.28
3
Adjusted Non-GAAP % change vs. prior year
12.5
%
8.1
%
20.7
%
21.9
%
34.0
%
18.2
%
21.0
%
Percentages of Revenue:
GAAP
Adjusted Non-GAAP
Gross profit
3.42
%
3.31
%
Operating expenses
2.28
%
2.08
%
Operating income
1.14
%
1.23
%
________________________________________ 1Includes a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's commitment, which it made in December 2023, to prepay the net present value of a future obligation as permitted under its opioid settlement agreements.
2Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income, Net.
3The sum of the components does not equal the total due to rounding.
Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.CENCORA, INC.
GAAP TO NON-GAAP RECONCILIATIONS
(in thousands, except per share data)
(unaudited)
Three Months Ended December 31, 2022
Gross Profit
Operating Expenses
Operating Income
Income Before Income Taxes
Income Tax Expense
Net Loss Attributable to Noncontrolling Interests
Net Income Attributable
to Cencora
Diluted Earnings
Per Share
GAAP
$
2,145,953
$
1,512,810
$
633,143
$
593,455
$
117,285
$
3,575
$
479,745
$
2.33
Gains from antitrust litigation settlements
(49,899
)
—
(49,899
)
(49,899
)
(11,659
)
—
(38,240
)
(0.19
)
LIFO expense
25,050
—
25,050
25,050
5,853
—
19,197
0.09
Turkey highly inflationary impact
3,584
—
3,584
3,986
—
—
3,986
0.02
Acquisition-related intangibles amortization
—
(71,878
)
71,878
71,878
16,795
(1,158
)
53,925
0.26
Litigation and opioid-related expenses
—
(12,706
)
12,706
12,706
2,969
—
9,737
0.05
Acquisition-related deal and integration expenses
—
(20,996
)
20,996
20,996
4,906
—
16,090
0.08
Restructuring and other expenses
—
(16,240
)
16,240
16,240
3,794
—
12,446
0.06
Recovery of non-customer note receivable
—
—
—
(1,148
)
—
—
(1,148
)
(0.01
)
Tax reform 1
—
—
—
(4,457
)
(8,364
)
—
3,907
0.02
Adjusted Non-GAAP
$
2,124,688
$
1,390,990
$
733,698
$
688,807
$
131,579
$
2,417
$
559,645
$
2.71
Percentages of Revenue:
GAAP
Adjusted
Non-GAAP
Gross profit
3.41
%
3.38
%
Operating expenses
2.41
%
2.21
%
Operating income
1.01
%
1.17
%
________________________________________1
Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income, Net.
Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.
CENCORA, INC.
SUMMARY SEGMENT INFORMATION
(in thousands)
(unaudited)
Three Months Ended December 31,
Revenue
2023
2022
% Change
U.S. Healthcare Solutions
$
65,183,802
$
56,236,579
15.9
%
International Healthcare Solutions
7,070,227
6,611,278
6.9
%
Intersegment eliminations
(1,196
)
(1,025
)
Revenue
$
72,252,833
$
62,846,832
15.0
%
Three Months Ended December 31,
Operating income
2023
2022
% Change
U.S. Healthcare Solutions
$
698,124
$
572,416
22.0
%
International Healthcare Solutions
187,595
161,282
16.3
%
Total segment operating income
885,719
733,698
20.7
%
Gains from antitrust litigation settlements
48,248
49,899
LIFO credit (expense)
48,445
(25,050
)
Turkey highly inflationary impact
(17,226
)
(3,584
)
Acquisition-related intangibles amortization
(165,724
)
(71,878
)
Litigation and opioid-related credit (expenses)
78,917
(12,706
)
Acquisition-related deal and integration expenses
(21,063
)
(20,996
)
Restructuring and other expenses
(34,441
)
(16,240
)
Operating income
$
822,875
$
633,143
30.0
%
Percentages of Revenue:
U.S. Healthcare Solutions
Gross profit
2.41
%
2.46
%
Operating expenses
1.34
%
1.45
%
Operating income
1.07
%
1.02
%
International Healthcare Solutions
Gross profit
11.56
%
11.17
%
Operating expenses
8.91
%
8.73
%
Operating income
2.65
%
2.44
%
Cencora, Inc. (GAAP)
Gross profit
3.42
%
3.41
%
Operating expenses
2.28
%
2.41
%
Operating income
1.14
%
1.01
%
Cencora, Inc. (Non-GAAP)
Adjusted gross profit
3.31
%
3.38
%
Adjusted operating expenses
2.08
%
2.21
%
Adjusted operating income
1.23
%
1.17
%
Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.
CENCORA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
December 31,
September 30,
2023
2023
ASSETS
Current assets:
Cash and cash equivalents
$
2,872,351
$
2,592,051
Accounts receivable, net
21,576,594
20,911,081
Inventories
18,652,240
17,454,768
Right to recover assets
1,242,978
1,314,857
Prepaid expenses and other
514,568
526,069
Total current assets
44,858,731
42,798,826
Property and equipment, net
2,117,283
2,135,171
Goodwill and other intangible assets
14,036,973
14,005,900
Deferred income taxes
218,325
200,667
Other long-term assets
3,458,985
3,418,182
Total assets
$
64,690,297
$
62,558,746
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
$
47,743,474
$
45,836,037
Accrued expenses and other
2,437,219
2,353,817
Short-term debt
592,779
641,344
Total current liabilities
50,773,472
48,831,198
Long-term debt
4,185,944
4,146,113
Accrued income taxes
335,293
310,676
Deferred income taxes
1,690,785
1,657,944
Accrued litigation liability
4,731,945
5,061,795
Other long-term liabilities
1,911,602
1,884,733
Total equity
1,061,256
666,287
Total liabilities and stockholders’ equity
$
64,690,297
$
62,558,746
CENCORA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
Three Months Ended December 31,
2023
2022
Operating Activities:
Net income
$
603,008
$
476,170
Adjustments to reconcile net income to net cash provided by operating activities
336,514
242,947
Changes in operating assets and liabilities, excluding the effects of acquisitions:
Accounts receivable
(504,086
)
(59,872
)
Inventories
(1,095,530
)
(1,178,035
)
Accounts payable
1,765,103
1,381,079
Other, net
(219,852
)
(152,209
)
Net cash provided by operating activities
885,157
710,080
Investing Activities:
Capital expenditures
(74,217
)
(75,727
)
Prefunded business acquisition
—
(1,438,124
)
Other, net
8,417
2,693
Net cash used in investing activities
(65,800
)
(1,511,158
)
Financing Activities:
Net debt repayments
(10,469
)
(10,518
)
Purchases of common stock 1
(385,533
)
(807,214
)
Exercises of stock options
10,926
21,863
Cash dividends on common stock
(105,690
)
(99,713
)
Employee tax withholdings related to restricted share vesting
(56,248
)
(65,217
)
Other, net
(4,655
)
(3,145
)
Net cash used in financing activities
(551,669
)
(963,944
)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
15,544
84,140
Increase (decrease) in cash, cash equivalents, and restricted cash
283,232
(1,680,882
)
Cash, cash equivalents, and restricted cash at beginning of period 2
2,752,889
3,593,539
Cash, cash equivalents, and restricted cash at end of period 2
$
3,036,121
$
1,912,657
________________________________________ 1
Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.
2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash, cash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:
December 31, 2023
September 30, 2023
December 31, 2022
September 30, 2022
Cash and cash equivalents
$
2,872,351
$
2,592,051
$
1,692,205
$
3,388,189
Restricted cash (included in Prepaid Expenses and Other)
99,796
97,722
159,599
144,980
Restricted cash (included in Other Long-Term Assets)
63,974
63,116
60,853
60,370
Cash, cash equivalents, and restricted cash
$
3,036,121
$
2,752,889
$
1,912,657
$
3,593,539
SUPPLEMENTAL INFORMATION REGARDING NON-GAAP FINANCIAL MEASURES
To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses the non-GAAP financial measures described below. The non-GAAP financial measures should be viewed in addition to, and not in lieu of, financial measures calculated in accordance with GAAP. These supplemental measures may vary from, and may not be comparable to, similarly titled measures by other companies.
The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the Company’s operating performance, to perform financial planning, and to determine incentive compensation. Therefore, the Company believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. The presented non-GAAP financial measures exclude items that management does not believe reflect the Company’s core operating performance because such items are outside the control of the Company or are inherently unusual, non-operating, unpredictable, non-recurring, or non-cash. We have included the following non-GAAP earnings-related financial measures in this release:
The Company also presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating current period results at the foreign currency exchange rates used in the comparable period in the prior year. The Company presents such constant currency financial information because it has significant operations outside of the United States reporting in currencies other than the U.S. dollar and this presentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. For the first quarter of fiscal 2024, (i) revenue of $72.3 billion was negatively impacted by foreign currency translation of $119 million, resulting in revenue on a constant currency basis of $72.4 billion, and (ii) operating income of $886 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a constant currency basis of $892 million. For the first quarter of fiscal 2024 in the International Healthcare Solutions segment, (i) revenue of $7.1 billion was negatively impacted by foreign currency translation of $119 million, resulting in revenue on a constant currency basis of $7.2 billion, and (ii) operating income of $188 million was negatively impacted by foreign currency translation of $6 million, resulting in operating income on a constant currency basis of $194 million.
In addition, the Company has provided non-GAAP fiscal year 2024 guidance for diluted earnings per share, operating income, effective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring or non-cash in nature. The Company does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company’s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. Similarly, the timing and amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable and cannot be reasonably estimated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130014076/en/
Bennett S. Murphy Senior Vice President, Head of Investor Relations and Treasury 610-727-3693 bennett.murphy@cencora.com
1 Year Cencora Chart |
1 Month Cencora Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions